DIBUTYL SEBACATE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
314.0 4.8 0 4 53.0 15 0.89
CAS
109433
UNII
4W5IH7FLNY
SYNONYMS
ZINC ID(s)
Availability
Present in 32 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02398318 2015-04-01 China Refractory Obsessive-Compulsive Disorder Deep Brain Stimulation Study Phase 2/Phase 3 Not Yet Recruiting
NCT02263417 2014-10-01 The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Dystonia Phase 0 Not Yet Recruiting
NCT02253498 2014-09-01 The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome Phase 0 Not Yet Recruiting
NCT01973478 2014-05-01 Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression Phase 3 Recruiting
NCT02076698 2014-03-01 Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy Phase 3 Recruiting
NCT01988688 2014-01-01 Pilot Study of Deep Brain Stimulation (DBS) in Area LC for Chronic Tinnitus Phase 1 Recruiting
NCT02377505 2013-01-01 Deep Brain Stimulation in Treatment Resistant Schizophrenia Phase 3 Recruiting
NCT01701544 2012-08-01 Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's. Phase 1/Phase 2 Enrolling By Invitation
NCT01608061 2012-05-01 ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease Phase 1/Phase 2 Active, Not Recruiting
NCT01678014 2012-04-01 Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa Phase 1 Recruiting
NCT01485276 2011-11-01 Combined Deep Brain Stimulation for Parkinson's Disease Phase 1/Phase 2 Withdrawn
NCT01703598 2011-09-01 Clinical Outcomes of Deep Brain Stimulator (DBS) Electrodes Placed Using Intraoperative Computed Tomography (CT) and Frameless Stereotaxis Phase 4 Recruiting
NCT01095263 2011-04-01 Effects of Deep Brain Stimulation in Treatment Resistant Major Depression Phase 1 Active, Not Recruiting
NCT01329133 2011-04-01 Deep Brain Stimulation and Obsessive-compulsive Disorder Phase 3 Recruiting
NCT01372722 2010-05-01 Deep Brain Stimulation (DBS) for Treatment Resistant Bipolar Disorder Phase 2/Phase 3 Recruiting
NCT02055261 2009-05-01 Pedunculopontine Nucleus Stimulation for Gait Disorders in Parkinson's Disease Phase 1/Phase 2 Completed
NCT00837486 2009-02-01 Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression Phase 2 Completed
NCT00634478 2008-10-01 Pre-lemniscal Radiation Deep Brain Stimulation for ET Phase 2/Phase 3 Withdrawn
NCT00773604 2008-06-01 Deep Brain Stimulation in Patients With Dystonia Phase 1/Phase 2 Active, Not Recruiting
NCT00640133 2008-03-01 Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder Phase 2 Recruiting
NCT00531726 2007-09-01 Berlin Deep Brain Stimulation Depression Study Phase 3 Recruiting
NCT00658125 2007-03-01 Deep Brain Stimulation (DBS) for Alzheimer's Disease Phase 1 Active, Not Recruiting
NCT00148889 2005-07-01 Double-Blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia Phase 3 Completed
NCT00101933 2003-12-01 SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy Phase 3 Active, Not Recruiting
NCT00792532 2003-07-01 Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes Phase 4 Recruiting

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Oral Capsule, Delayed Action 6.41MG
Oral Capsule, Delayed Action, Enteric Coated, Hard Gelatin 3.02MG
Oral Capsule, Enteric Coated Pellets 0.89MG
Oral Capsule, Extended Release 10MG
Oral Capsule, Hard Gelatin 3.83MG
Oral Capsule, Sustained Action 8.82MG
Oral Granule, Enteric Coated 43.2MG
Oral Tablet 6MG
Oral Tablet, Extended Release 19.07MG
Oral Tablet, Film Coated
Oral Tablet, Sustained Action 1.11MG

More Information

Usage Over Time

Comments